Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.17), $0.23 better than the analyst estimate of ($1.40). Revenue for the quarter came in at $12.61 million versus the consensus estimate of $11.66 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.